Q2 Earnings Estimate for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – Research analysts at HC Wainwright issued their Q2 2025 earnings estimates for Annexon in a research report issued on Tuesday, March 4th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS and FY2029 earnings at $0.28 EPS.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05).

ANNX has been the topic of several other reports. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Annexon in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $15.80.

Annexon Trading Down 2.9 %

ANNX opened at $2.68 on Thursday. The firm’s 50-day moving average price is $3.85 and its 200 day moving average price is $5.38. Annexon has a twelve month low of $2.30 and a twelve month high of $8.40. The firm has a market capitalization of $285.67 million, a PE ratio of -2.55 and a beta of 1.14.

Hedge Funds Weigh In On Annexon

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANNX. BNP Paribas Financial Markets acquired a new stake in Annexon in the fourth quarter valued at approximately $59,000. CANADA LIFE ASSURANCE Co purchased a new stake in Annexon during the 4th quarter valued at approximately $77,000. E Fund Management Co. Ltd. lifted its position in Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Forefront Analytics LLC grew its position in Annexon by 56.8% in the 4th quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after buying an additional 5,950 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Annexon during the fourth quarter worth about $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.